生物制剂时代重新定义支气管镜在重症未控制哮喘评估中的作用:一项前瞻性研究
支气管镜发现胃食管反流病征象21%、声带功能障碍5%、气管异常3%,支气管抽吸物培养细菌27%、真菌14%,91%支气管活检检出嗜酸性粒细胞;仅1例中度出血。常规支气管镜安全,有助于更好表型和个体化管理。
要点
- 重症未控制哮喘患者常规支气管镜安全,仅1例中度出血。
- 支气管镜可发现胃食管反流、声带功能障碍等共病征象。
- 支气管活检嗜酸性粒细胞与血嗜酸性粒细胞相关但不完全一致。
核心结论
- 对适合生物制剂治疗的重症未控制哮喘患者,常规支气管镜是安全操作,有助于更好表型和个体化管理。
研究设计与样本
- 患者临床表型分为T2过敏型(28%)、T2嗜酸型(64%)和非T2型(8%),均行支气管镜检查并系统收集内镜、微生物和活检嗜酸性粒细胞数据。
主要发现
- 支气管镜检出胃食管反流病征象21%、声带功能障碍5%、气管异常3%。
- 支气管抽吸物培养细菌阳性27%、真菌阳性14%。
- 聚类分析识别出非特异型、上气道型和感染型三个簇,感染型与黏膜下嗜酸性粒细胞增多关联较少。
- 91%的支气管活检检出嗜酸性粒细胞;尽管与血嗜酸性粒细胞相关,5例T2表型患者支气管活检无嗜酸性粒细胞,3例非T2表型患者支气管活检有嗜酸性粒细胞。
- 仅1例患者发生中度出血。
临床怎么用
- 对拟启动生物制剂治疗的重症未控制哮喘患者,可考虑常规支气管镜以评估共病、感染及局部嗜酸性粒细胞炎症。
- 支气管镜结果可能影响表型分类和治疗个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Severe uncontrolled asthma (SUA) is frequently treated with biologic therapy if a T2 phenotype is found. Bronchoscopy is not routinely recommended in these patients unless a specific indication to rule out comorbidities is present. RESEARCH QUESTION: Is routine bronchoscopy safe and useful in phenotyping and endotyping patients with SUA before the indication of a biologic therapy? STUDY DESIGN AND METHODS: Prospective study of consecutive patients with SUA who were referred to a specialized asthma clinic to assess the indication of a biologic therapy. Patients were clinically phenotyped as T2-allergic, T2-eosinophilic, and non-T2. All patients underwent bronchoscopy, and systematic data collection of endoscopic findings, microbiology of bronchial aspirate, and presence of eosinophils in bronchial biopsy were recorded and compared between asthma phenotypes. Cluster analysis was performed accordingly. RESULTS: One hundred patients were recruited and classified as T2-allergic (28%), T2-eosinophilic (64%), and non-T2 (8%). On bronchoscopy, signs of gastroesophageal reflux disease were detected in 21%, vocal cord dysfunction in 5%, and tracheal abnormalities in 3%. Bronchial aspirate culture isolated bacteria in 27% of patients and fungi in 14%. Three clusters were identified: nonspecific, upper airway, and infection, the latter being less frequently associated with submucosal eosinophilia. Eosinophils were detected in 91% of bronchial biopsies. Despite a correlation to blood eosinophils, five patients with T2-phenotypes showed no eosinophils in bronchial biopsy, and three patients with non-T2 showed eosinophils in bronchial biopsy. Only one patient had moderate bleeding. INTERPRETATION: Routine bronchoscopy in SUA eligible for biologic therapy is a safe procedure that can help to better phenotype and personalize asthma management.
引用
- Cosío BG, Shafiek H, Mosteiro M, et al. Redefining the Role of Bronchoscopy in the Workup of Severe Uncontrolled Asthma in the Era of Biologics: A Prospective Study. Chest. 2023. PMID: 36921895. doi:10.1016/j.chest.2023.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。